Pretarsal application of botulinum toxin for treatment of blepharospasm

M Aramideh, B W Ongerboer de Visser, J W Brans, J H Koelman, J D Speelman, M Aramideh, B W Ongerboer de Visser, J W Brans, J H Koelman, J D Speelman

Abstract

The response to botulinum toxin type A was compared after two injection techniques in 45 patients with blepharospasm. Initially, patients were treated according to a triple injection technique; two injections into the upper eyelid and one injection into the lower eyelid. Subsequently, without altering the dose, the same patient group received two further injections into the pretarsal portion of the orbicularis oculi muscle of the upper lid. Triple injections were given in 227 treatments, of which 81% were successful. Mean duration of benefit was 8.5 weeks. Additional pretarsal injections were given in 183 treatment sessions. The number of successful treatments significantly increased, to 95% (P < 0.001), and the mean duration of benefit increased to 12.5 weeks (P < 0.001). Ptosis occurred significantly less often after pretarsal injections (P < 0.01). Patients with combined blepharospasm and involuntary levator palpebrae inhibition responded better to the pretarsal injection technique.

References

    1. J Neurol Neurosurg Psychiatry. 1976 Dec;39(12):1204-9
    1. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):767-72
    1. Ann Neurol. 1983 Apr;13(4):402-11
    1. Arch Ophthalmol. 1985 Mar;103(3):347-50
    1. Brain. 1985 Sep;108 ( Pt 3):593-608
    1. Arch Neurol. 1986 Apr;43(4):380-2
    1. Muscle Nerve. 1987 Jul-Aug;10(6):552-5
    1. Adv Neurol. 1988;49:73-84
    1. Arch Ophthalmol. 1977 Aug;95(8):1437-41
    1. Arch Otolaryngol Head Neck Surg. 1988 Dec;114(12):1407-12
    1. Eye (Lond). 1988;2 ( Pt 4):435-9
    1. J Neurol Neurosurg Psychiatry. 1992 May;55(5):369-71
    1. Brain. 1994 Feb;117 ( Pt 1):27-38
    1. Muscle Nerve. 1994 Jun;17(6):623-31
    1. Mov Disord. 1994 Jul;9(4):395-402
    1. Neurology. 1995 May;45(5):897-902
    1. Br J Ophthalmol. 1951 Jun;35(6):339-51

Source: PubMed

3
Subscribe